Организация медицинской помощи при остром коронарном синдроме в рамках федерального проекта «Борьба с сердечно-сосудистыми заболеваниями»: результаты и перспективы

Инфаркт миокарда (ИМ) продолжает сохранять статус одного из ключевых жизнеугрожающих сердечно-сосудистых заболеваний с высоким бременем заболеваемости и смертности, включая население трудоспособного возраста. В рамках федерального проекта "Борьба с сердечно-сосудистыми заболеваниями" в Российской Федерации в 2019-2024гг была проведена масштабная модернизация системы оказания медицинской помощи при остром коронарном синдроме и ИМ: расширена сеть региональных сосудистых центров, оптимизирована маршрутизация пациентов, что позволило увеличить охват чрескожным коронарным вмешательством при ИМ с подъемом сегмента ST с 56% до 77%, а при ИМбпST — с 21% до 48%, и достичь снижения смертности от ИМ на 100 тыс. населения на 19,6%, а больничной летальности от ИМ — на 32%. Однако сохраняются межрегиональные различия, в связи с чем необходима дальнейшая работа над повышением доступности и своевременности реперфузионной терапии. В рамках федерального проекта "Борьба с сердечнососудистыми заболеваниями" Национального проекта "Продолжительная и активная жизнь" будет происходить мониторинг целевого показателя охвата реперфузионной терапией больных ИМ, госпитализированных в первые сутки от начала заболевания, уровень которого должен достичь 95% к 2030г. Реализация дополнительных мероприятий позволит сократить дифференциацию показателей между регионами, снизить смертность от болезней системы кровообращения и достичь национальных целей по увеличению продолжительности жизни.

1. Аверков О.В., Арутюнян Г.К., Дупляков Д.В. и др. Острый инфаркт миокарда с подъемом сегмента ST электрокардиограммы. Клинические рекомендации 2024. Российский кардиологический журнал. 2025;30(3): 6306. doi:10.15829/1560-4071-2025-6306. EDN: IVJCUK.

2. Аверков О.В., Арутюнян Г.К., Дупляков Д.В. и др. Острый коронарный синдром без подъема сегмента ST электрокардиограммы. Клинические рекомендации 2024. Российский кардиологический журнал. 2025;30(5): 6319. doi:10.15829/1560-4071-2025-6319. EDN: CXJUIB.

3. Williams C, Fordyce CB, Cairns JA, et al. Temporal Trends in Reperfusion Delivery and Clinical Outcomes Following Implementation of a Regional STEMI Protocol: A 12-Year Perspective. CJC Open. 2022;5(3):181-90. doi:10.1016/j.cjco.2022.11.015.

4. Jortveit J, Pripp AH, Halvorsen S. Outcomes after delayed primary percutaneous coronary intervention vs. pharmaco-¬invasive strategy in ST-segment elevation myocardial infarction in Norway. Eur Heart J Cardiovasc Pharmacother. 2022;8(5):442-51. doi:10.1093/ehjcvp/pvab041.

5. Eastwood K, Howell S, Nehme Z, et al. Impact of a mass media campaign on presentations and ambulance use for acute coronary syndrome. Open Heart. 2021;8:e001792. doi:10.1136/openhrt2021-001792.

6. Thygesen K, Alpert JS, Jaffe AS, et al.; ЕОК Scientific Document Group. Fourth universal definition of myocardial infarction (2018). Eur Heart J. 2019;40:237-69. doi:10.1161/CIR.0000000000000617.

7. Diercks DB, Peacock WF, Hiestand BC, et al. Frequency and consequences of recording an electrocardiogram >10 minutes after arrival in an emergency room in non-¬STsegment elevation acute coronary syndromes (from the CRUSADE Initiative). Am J Cardiol. 2006;97:437-42. doi:10.1016/j.amjcard.2005.09.073.

8. Schmitt C, Lehmann G, Schmieder S, et al. Diagnosis of acute myocardial infarction in angiographically documented occluded infarct vessel: limitations of ST-segment elevation in standard and extended ECG leads. Chest. 2001;120:1540-6. doi:10.1378/chest.120.5.1540.

9. Fesmire FM, Percy RF, Bardoner JB, et al. Usefulness of automated serial 12 lead ECG monitoring during the initial emergency department evaluation of patients with chest pain. Ann Emerg Med. 1998;31:3-11. doi:10.1016/S0196-0644(98)70274-4.

10. Rouan GW, Lee TH, Cook EF, et al. Clinical characteristics and outcome of acute myocardial infarction in patients with initially normal or nonspecific electrocardiograms (a report from the Multicenter Chest Pain Study). Am J Cardiol. 1989;64:1087-92. doi:10.1016/00029149(89)90857-6.

11. McCarthy BD, Wong JB, Selker HP. Detecting acute cardiac ischemia in the emergency department. J Gen Intern Med. 1990;5:365-73. doi:10.1007/BF02600409.

12. Savonitto S, Ardissino D, Granger CB, et al. Prognostic value of the admission electrocardiogram in acute coronary syndromes. JAMA. 1999;281:707-13. doi:10.1001/jama.281.8.707.

13. Дроздов Д.В., Макаров Л.М., Иртюга О.Б. и др. Регистрация электрокардиограммы покоя в 12 общепринятых отведениях взрослым и детям 2023. Методические рекомендации. Российский кардиологический журнал. 2023;28(10):5631. doi:10.15829/1560-4071-2023-5631.

14. Bainey KR, Armstrong PW, Zheng Y, et al. Pharmacoinvasive Strategy Versus Primary Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction in Clinical Practice: Insights From the Vital Heart Response Registry. Circ Cardiovasc Interv. 2019;12(10):e008059. doi:10.1161/CIRCINTERVENTIONS.119.008059.

15. Boersma E, Maas AC, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet. 1996;348:771-5. doi:10.1016/s0140-6736(96)02514-7.

16. Boersma E. Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. Eur Heart J. 2006;27:779-88. doi:10.1093/eurheartj/ehi810.

17. Byrne RA, Rossello X, Coughlan JJ, et al.; ESC Scientific Document Group. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720-826. doi:10.1093/eurheartj/ehad191.

18. O’Gara PT, Kushner FG, Ascheim DD, et al.; American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127(4):e362-425. doi:10.1161/CIR.0b013e3182742cf6.

19. Steg PG, James SK, Atar D, et al. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC); ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33(20):2569-619. doi:10.1093/eurheartj/ehs215.

20. Morrison LJ, Verbeek PR, McDonald AC, et al. Mortality and prehospital thrombolysis for acute myocardial infarction: a meta-analysis. J Am Med Assoc. 2000;283:2686-92. doi:10.1001/jama.283.20.2686.

21. McCaul M, Lourens A, Kredo T. Pre-hospital versus in-hospital thrombolysis for ST-elevation myocardial infarction Cochrane Database Syst Rev. 2014:(9):CD010191. doi:10.1002/14651858.CD010191.pub2.

22. Bonnefoy E, Steg PG, Boutitie F, et al. Comparison of primary angioplasty and pre-hospital fibrinolysis in acute myocardial infarction (CAPTIM) trial: a 5 year follow-up. Eur Heart J. 2009;30(13):1598-606. doi:10.1093/eurheartj/ehp156.

23. Armstrong PW, Gershlick AH, Goldstein P, et al.; STREAM Investigative Team. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med. 2013;368(15):1379-87. doi:10.1056/NEJMoa1301092.

24. Ellis SG, da Silva ER, Heyndrickx G, et al.; RЕSCUE Investigators. Randomized comparison of rescue angioplasty with conservative management of patients with early failure of thrombolysis for acute anterior myocardial infarction. Circulation. 1994;90(5):2280-4. doi:10.1161/01.cir.90.5.2280.

25. Sutton AGC, Campbell PG, Graham R, et al. A randomized trial of rescue angioplasty versus a conservative approach for failed fibrinolysis in ST-segment elevation myocardial infarction: the Middlesbrough Early Revascularization to Limit INfarction (MERLIN) trial. J Am Coll Cardiol. 2004;44:287-96. doi:10.1016/j.jacc.2003.12.059.

26. Wijeysundera H, Vijayaraghavan R, Nallamothu B, et al. Rescue Angioplasty or Repeat Fibrinolysis After Failed Fibrinolytic Therapy for ST-Segment Myocardial Infarction: A Meta--Analysis of Randomized Trials. JACC. 2007;49(4):422-30. doi:10.1016/j.jacc.2006.09.033.

27. Collet JP, Montalesot G, Le May M, et al. Percutaneous coronary intervention after fibrinolysis: a multiple meta-analyses approach according to the type of strategy. J Am Coll Cardiol. 2006;48:1326-35. doi:10.1016/j.jacc.2006.03.064.

28. Appleton DL, Abbate A, Biondi-¬Zoccai GGL. Late percutaneous coronary intervention for the totally occluded infarct-¬related artery: a meta-analysis of the effects on cardiac function and remodeling. Catheter Cardiovasc Interv. 2008;71:772-81. doi:10.1002/ccd.21468.

29. Borgia F, Goodman SG, Halvorsen S, et al. Early routine percutaneous coronary intervention after fibrinolysis vs. standard therapy in ST-segment elevation myocardial infarction: a meta-analysis. Eur Heart J. 2010;31(17):2156-69. doi:10.1093/eurheartj/ehq204.

30. D’Souza SP, Mamas MA, Fraser DG, et al. Routine early coronary angioplasty versus ischaemia-¬guided angioplasty after thrombolysis in acute ST-elevation myocardial infarction: a meta-analysis. Eur Heart J. 2011;32(8):972-82. doi:10.1093/eurheartj/ehq398.

31. Hochman JS, Lamas GA, Buller CE, et al.; Occluded Artery Trial Investigators. Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med. 2006; 355(23):2395-407. doi:10.1056/NEJMoa066139.

32. Schömig A, Mehilli J, Antoniucci D, et al. Mechanical Reperfusion in Patients With Acute Myocardial Infarction Presenting More Than 12 Hours From Symptom Onset: A Randomized Controlled Trial. JAMA. 2005;293(23):2865-72. doi:10.1001/jama.293.23.2865.

33. Nadrepepa G, Kastrati A, Mehilli J, et al. Mechanical reperfusion and long-term mortality in patients with acute myocardial infarction presenting 12 to 48 hours from onset of symptoms. JAMA. 2009;301(5):487-8. doi:10.1001/jama.2009.32.

34. Bouisset F, Gerbaud E, Bataille V, et al. Percutaneous myocardial revascularization in latepresenting patients with STEMI. J Am Coll Cardiol. 2021;78:1291-305. doi:10.1016/j.jacc.2021.07.039.

35. Busk M, Kaltoft A, Nielsen SS, et al. Infarct size and myocardial salvage after primary angioplasty in patients presenting with symptoms for <12 h vs. 12-72 h. Eur Heart J. 2009;30:1322-30. doi:10.1093/eurheartj/ehp113.

36. Ioannidis JP, Katritsis DG. Percutaneous coronary intervention for late reperfusion after myocardial infarction in stable patients. Am Heart J. 2007;154(6):1065-71. doi:10.1016/j.ahj.2007.07.049.

37. Menon V, Pearte CA, Buller CE, et al. Lack of benefit from percutaneous intervention of persistently occluded infarct arteries after the acute phase of myocardial infarction is time independent: insights from Occluded Artery Trial. Eur Heart J. 2009;30(2):183-91. doi:10.1093/eurheartj/ehn486.

38. Wald DS, Morris JK, Wald NJ, et al. & PRAMI Investigators. Randomized trial of preventive angioplasty in myocardial infarction. The New England journal of medicine. 2013;369(12):1115-23. doi:10.1056/NEJMoa1305520.

39. Engstrøm T, Kelbæk H, Helqvist S, et al. Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI 3 — PRIMULTI): an open-label, randomised controlled trial. Lancet. 2015;386:665-71. doi:10.1016/s0140-6736(15)60648-1.

40. Smits PC, Abdel-¬Wahab M, Neumann FJ, et al. Fractional flow reserve-¬guided multivessel angioplasty in myocardial infarction. N Engl J Med. 2017;376:1234-44. doi:10.1056/NEJMoa1701067.

41. Mehta SR, Wang J, Wood DA, et al.; COMPLETE Trial Investigators. Complete Revascularization vs Culprit Lesion-¬Only Percutaneous Coronary Intervention for Angina--Related Quality of Life in Patients With ST-Segment Elevation Myocardial Infarction: Results From the COMPLETE Randomized Clinical Trial. JAMA cardiology. 2022;7(11):1091-9. doi:10.1001/jamacardio.2022.3032.

42. Gershlick AH, Khan JN, Kelly DJ, et al. Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease: the CvLPRIT trial. J Am Coll Cardiol. 2015;65:963-72. doi:10.1016/j.jacc.2014.12.038.

43. Chin CT, L’Allier P, Neumann FJ, et al. The Compare-¬Acute trial of fractional flow reserve--guided multivessel angioplasty in myocardial infarction. EuroIntervention: journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 2017;13(5):e613 e616. doi:10.4244/EIJV13I5A96.

44. Diletti R, den Dekker WK, Bennett J; BIOVASC Investigators. Immediate versus staged complete revascularisation in patients presenting with acute coronary syndrome and multivessel coronary disease (BIOVASC): a prospective, open-label, non-inferiority, randomised trial. Lancet. 2023;401(10383):1172-82. doi:10.1016/S0140-6736(23)00351-3.

45. Biscaglia S, Guiducci V, Escaned J, et al.; FIRE Trial Investigators. Complete or Culprit-Only PCI in Older Patients with Myocardial Infarction. N Engl J Med. 2023;389(10):88998. doi:10.1056/NEJMoa2300468.

46. Reichlin T, Twerenbold R, Reiter M, et al. Introduction of high-sensitivity troponin assays: impact on myocardial infarction incidence and prognosis. Am J Med. 2012;125:1205-13. doi:10.1016/j.amjmed.2012.07.015.

47. Сhapman AR, Lee KK, McAllister DA, et al. Association of High-¬Sensitivity Cardiac Troponin I Concentration With Cardiac Outcomes in Patients With Suspected Acute Coronary Syndrome. JAMA. 2017;318:1913-24. doi:10.1001/jama.2017.17488.

48. Mueller C, Giannitsis E, Mockel M, et al., Biomarker Study Group of the ESC ACCA. Rapid rule out of acute myocardial infarction: novel biomarker-¬based strategies. Eur Heart J Acute Cardiovasc Care. 2017;6:218-22. doi:10.1177/2048872616653229.

49. Pickering JW, Than MP, Cullen L, et al. Rapid Rule-out of Acute Myocardial Infarction With a Single HighSensitivity Cardiac Troponin T Measurement Below the Limit of Detection: A Collaborative Meta-analysis. Ann Intern Med. 2017;166:715-3724. doi:10.7326/M16-2562.

50. Miller-¬Hodges E, Anand A, Shah ASV, et al. High-¬Sensitivity Cardiac Troponin and the Risk Stratification of Patients With Renal Impairment Presenting With Suspected Acute Coronary Syndrome. Circulation. 2018;137:425-35. doi:10.1161/CIRCULATIONAHA.117.030320.

51. Townsend N, Wilson L, Bhatnagar P, et al. Cardiovascular disease in Europe: epidemiological update 2016. European Heart Journal. 2016;37(42):3232-45. doi:10.1093/eurheartj/ehw334.

52. Abu-¬Assi E, López-¬López A, González-¬Salvado V, et al. The Risk of Cardiovascular Events After an Acute Coronary Event Remains High, Especially During the First Year, Despite Revascularization. Revista Espanola de Cardiologia. 2016;69(1):11-8. doi:10.1016/j.rec.2015.06.015.

53. Bouisset F, Ruidavets J-B, Dallongeville J, et al. Comparison of Short- and Long-¬Term Prognosis between ST-Elevation and Non-¬ST-Elevation Myocardial Infarction. Journal of Clinical Medicine. 2021;10(2):180. doi:10.3390/jcm10020180.